Clinigen Share Discussion Threads

[simon gordon] 07/11/2012 06:45

Numis initiates buy on Clinigen Group, target price 240p

[simon gordon] 06/11/2012 13:09

Numis - 1/11/12:

06/13
T/O - 97.1m
PBT - 17m
EPS - 14.5p
DPS - 1.85p

06/14
T/O - 110.1m
PBT - 19.6m
EPS - 16.7p
DPS - 2.23p

[bob monkhouse] 29/10/2012 20:23

subbed to keep an eye on

[simon gordon] 29/10/2012 20:17

Citywire - 17/10/12:



After a quiet August, Cazenove UK Smaller Companies manager Paul Marriage and co-manager John Warren bought shares in two new companies and exited a handful of stocks during an active September.

The proceeds of these sales have been invested in topping up a number of diverse positions across the fund including into car dealership Lookers (LOOK.L) and the IPO of drugs distribution specialist Clinigen (CLINC.L). The latter supplies a range of drugs involved in late-stage clinical trials, and Marriage said it also had one extremely profitable drug of its own and is looking to build on this success with a number of other products.

Marriage described Clinigen as 'the type of niche UK leader that we like, and with a good sell-down from the retiring founder we liked the IPO and pricing'.

'Historically, the stock market history of drug distributors has been reasonable, and specialist pharma companies with sales and profits have more recently been much preferred to their loss-making biotech peers.'

[tech] 01/10/2012 09:35

Bought a few today, looks interesting

[dasv] 28/9/2012 08:56

simon - I'm in here - thanks for the heads up.

[simon gordon] 27/9/2012 17:56

Posted on iii by Stuffee - 22/9/12:

Clinigen starts dealings next week. It is involved in drug testing for pharmaceutics companies as well as developing its own, life saving, drugs. It has grown rapidly over last two years and achieved adjusted net earnings of £11m for year to June 2012 with further significant growth expected.. In the Sunday Times table, it was the UK's fastest growing private company.. At Placing Price of 164p, it is capitalised at £135m, with a historic PE of 12 - pretty modest for high growth company in this sector.

It aims to be the leading global ciinical drug trial specialist..Providing price doesn't run away too much next week,, I feel involvement could be rewarding.

=======

£11m divided by 82.5m shares = 13.3p

180p divided by 13.3p = 13.5x historic

Looks good value for a defensive "growth" stock that is well capitalised and has a uber dynamic history.

[aishah] 27/9/2012 13:18

Looks interesting

[scientologyweirdo] 19/9/2012 07:38

Clinigen Group plc



Fundraising of £50m



Admission to AIM with market capitalisation of £135m



Clinigen Group plc, the global specialty pharmaceuticals and pharmaceutical services business, is to be admitted to AIM with a market capitalisation of £135 million.



The Placing, conducted by Numis Securities Limited ("Numis Securities"), has raised £50 million from institutional investors, including £10 million of new money for the Company before expenses, at a price of 164p per share. Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN.



Placing statistics






Placing Price

Number of Ordinary Shares in issue immediately following the Placing

Market Capitalisation at the Placing Price


164p per share

82,555,585 shares

£135.4 million




Number of New Ordinary Shares being placed on behalf of the Company

Number of Sale Shares being sold by Selling Shareholders*

Total number of Placing Shares*


6,097,561 shares



24,402,439 shares

30,500,000 shares




Placing Shares as a percentage of the Enlarged Share Capital*


36.9 %














Gross proceeds of the Placing


£50 million




Estimated net proceeds of the Placing receivable by the Company


£6.6 million




Estimated net proceeds of the Placing receivable by the Selling Shareholders*


£38.5 million




*Note: does not include any Ordinary Shares which may be sold pursuant to the over-allotment option granted by certain Selling Shareholders to Numis under which such Selling Shareholders may be required to sell up to 3,050,000 additional Ordinary Shares at the Placing Price.



The Business



· Clinigen is a fast-growing global specialty pharmaceuticals and pharmaceutical services business headquartered in the UK, with offices in the US and Japan.

· The Clinigen Group was formed in 2010 and comprises two divisions - Services and Products.

· Within the Services division, there are two operations: ClinigenCTS, which offers Clinical Trial Supply services, and ClinigenGAP, which offers Global Access Program ("GAP") services.

· The Products division owns and supplies Foscavir® (a hospital-only drug which is used in the treatment of cytomegalovirus and which was acquired from AstraZeneca in 2010) and intends to acquire, and grow sales of, additional niche hospital-only drugs.

· Taking into account both sales of Foscavir® and the GAP programs currently within the Services division, Clinigen manages the supply of drugs into a total of 53 countries. These drugs are used in the therapeutic areas of leukaemia (and other oncology), haematology, transplantation, anti-infective, pain management, gastrointestinal and hospital and critical care, as well as orphan diseases. Clinigen helps patients around the world with unmet medical needs by supplying their pharmacist or physician with the drugs these patients require.



Peter George, Chief Executive Officer, said:



"After a period of sustained international growth, a listing of our shares is key and the next logical step in our development. We aim to maintain our strong growth record - based on our unique business model - both organically and through the acquisition of new pharmaceutical products.



"The listing will provide us with additional financial flexibility which, together with our strong balance sheet and the funds raised for the Company, will support our on-going expansion."